Drug Profile


Alternative Names: Anti-interleukin 6 monoclonal antibody; BE-8

Latest Information Update: 19 Feb 2008

Price : $50

At a glance

  • Originator OPi
  • Class Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Lymphoma; Multiple myeloma; Post-transplant lymphoproliferative disorder

Most Recent Events

  • 30 Mar 2005 Phase-I/II clinical trials in Lymphoma in France (unspecified route)
  • 30 Mar 2005 Phase-II clinical trials in Multiple myeloma in France (unspecified route)
  • 31 Mar 2004 Phase-II clinical trials in Post-transplant lymphoproliferative disorder in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top